Uncategorised - European Medical Journal

AI-Enhanced Prostate Biopsies: Improving Precision and Efficiency

AI is revolutionising prostate cancer diagnostics by enhancing imaging accuracy and reducing interoperator variability.

Neighbourhood Disadvantage Tied to Worse Outcomes in Idiopathic Pulmonary Fibrosis

Living in disadvantaged neighbourhoods worsens lung function and raises mortality risk for idiopathic pulmonary fibrosis patients, especially those with milder disease, according to a new study.

Antipsychotics Linked to Worsening Behaviour in Long-Term Care Residents

Antipsychotics may worsen behavioral symptoms in long-term care residents, according to a large Canadian study. Researchers found a significant association between antipsychotic use and behavioral deterioration, urging caution in prescribing these medications.

Knowledge Gaps Found in Antiseizure Medications and Birth Control: AES 2024

The study surveyed 107 people, aged 18 to 49, who were taking ASMs, asking about their medication use, pregnancy plans, and contraceptive methods…

contract

Dr Dietmar Berger appointed as Gilead’s next Chief Medical Officer

Dr Dietmar Berger is set to join Gilead Sciences as Chief Medical Officer on 2 January 2025 – succeeding Dr Merdad Parsey.

Carrageenan Linked to Insulin Resistance and Inflammation in Overweight Individuals

Carrageenan, a widely used food additive, may worsen insulin resistance and inflammation in overweight individuals, a new study reveals, sparking concerns over its impact on metabolic health.

The Role of Eosinophils in Allergic Asthma

Benralizumab has shown efficacy in reducing asthma exacerbations and controlling symptoms in severe eosinophilic asthma.

Risk-Reducing Surgery for BRCA Carriers: SABCS 2024

Risk-reducing surgeries, including bilateral mastectomy (RRM) and salpingo-oophorectomy (RRSO), are associated with improved survival outcomes in BRCA-mutation carriers diagnosed with breast cancer at or before age 40, according to a study presented at the 2024 San Antonio Breast Cancer Symposium (SABCS).

COMET Trial Suggests Active Monitoring for Low-Risk DCIS: SABCS 2024

Active monitoring may be a safe and effective treatment option for patients with low-risk ductal carcinoma in situ (DCIS), according to the findings of the COMET trial presented at the San Antonio Breast Cancer Symposium (SABCS) 2024.

Melanoma Survivors Face 57% Increased Risk of Malignancies

Survivors of cutaneous melanoma (CM) face a 57% increased risk of developing second primary malignancies (SPMs) compared to the general population, according to groundbreaking research from a recent analysis of SEER database data spanning two decades.